Prelude Therapeutics Incorporated
PRLD
$4.66
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.64M | 6.50M | -- | -- | 4.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.64M | 6.50M | -- | -- | 4.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.64M | 6.50M | -- | -- | 4.00M |
| SG&A Expenses | 4.90M | 5.21M | 6.41M | 5.79M | 6.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.69M | 26.92M | 32.19M | 34.61M | 37.83M |
| Operating Income | -16.05M | -20.42M | -32.19M | -34.61M | -33.83M |
| Income Before Tax | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M |
| EBIT | -16.05M | -20.42M | -32.19M | -34.61M | -33.83M |
| EBITDA | -15.63M | -19.99M | -31.76M | -34.17M | -33.34M |
| EPS Basic | -0.21 | -0.26 | -0.41 | -0.42 | -0.38 |
| Normalized Basic EPS | -0.12 | -0.16 | -0.26 | -0.26 | -0.24 |
| EPS Diluted | -0.21 | -0.26 | -0.41 | -0.42 | -0.38 |
| Normalized Diluted EPS | -0.12 | -0.16 | -0.26 | -0.26 | -0.24 |
| Average Basic Shares Outstanding | 79.71M | 76.13M | 75.99M | 75.99M | 75.87M |
| Average Diluted Shares Outstanding | 79.71M | 76.13M | 75.99M | 75.99M | 75.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |